Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1890971 | 0.92 | RAB9A (0.47) | IRAK4RAB9ANPC1BACE1KDM4E | |
| SCHEMBL1883579 | 0.88 | RAB9A (0.59) | IRAK4RAB9ANPC1RPS6KA2PKM | |
| SCHEMBL1884510 | 0.86 | IRAK4 (0.48) | IRAK4RAB9ANPC1BACE1RPS6KA2 | |
| SCHEMBL1890286 | 0.86 | RAB9A (0.57) | RAB9ANPC1PKMSMN1; SMN2HTT | |
| SCHEMBL1883576 | 0.81 | RAB9A (0.58) | IRAK4RAB9ANPC1SMN1; SMN2HRH4 | |
| SCHEMBL1884504 | 0.77 | RAB9A (0.45) | IRAK4RAB9ANPC1BACE1KDR | |
| SCHEMBL1889444 | 0.77 | IRAK4 (0.42) | IRAK4RAB9ANPC1BACE1RPS6KA2 | |
| SCHEMBL12417686 | 0.73 | RAB9A (0.53) | RAB9ANPC1KDM4ETP53SMN1; SMN2 | |
| SCHEMBL1889246 | 0.72 | RAB9A (0.52) | RAB9ANPC1RPS6KA2KDM4ETP53 | |
| SCHEMBL30369772 | 0.72 | NPC1 (0.71) | IRAK4RAB9ANPC1BACE1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1887002-B1 | CARBOXAMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8304437-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | ARIMORI SADAYUKI | 2011-07-14 | — | — | US | disclosed |
| US-7935716-B2 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090076063-A1 | Carboxamide compound and use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1887002-A1 | CARBOXAMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076063-A1 | Carboxamide compound and use of the same | CBR3, SIRT2, SIRT1 | IRAK4 2187/4885RAB9A 1024/4885NPC1 1710/4885 |
| US-20110172276-A1 | CARBOXAMIDE COMPOUND AND USE OF THE SAME | CBR3, SIRT2, SIRT1 | IRAK4 2187/4885RAB9A 1024/4885NPC1 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.